FDA Drug Recalls

Recalls / Class II

Class IID-0330-2023

Product

Tacrolimus Capsules, USP, 0.5 mg, 100-count bottle, Rx Only, Mfd. by Dr. Reddy's Laboratories Limited, Bachupally - 500 090, INDIA; NDC 55111-525-01.

Brand name
Tacrolimus
Generic name
Tacrolimus
Active ingredient
Tacrolimus
Route
Oral
NDCs
55111-525, 55111-526, 55111-527
FDA application
ANDA090509
Affected lot / code info
Lot # C2106445; Exp. 03/2024

Why it was recalled

Presence of Foreign Tablets/Capsules: Presence of one Tacrolimus 1 mg capsule co-mingled in a bottle containing and labeled as Tacrolimus 0.5 mg capsules.

Recalling firm

Firm
Dr. Reddy's Laboratories, Inc.
Manufacturer
Dr. Reddy's Laboratories Limited
Notification channel
Letter
Type
Voluntary: Firm initiated
Address
107 College Rd E, N/A, Princeton, New Jersey 08540-6623

Distribution

Quantity
4,320 bottles
Distribution pattern
Nationwide in the USA

Timeline

Recall initiated
2023-02-08
FDA classified
2023-02-21
Posted by FDA
2023-03-01
Status
Ongoing

Source: openFDA Drug Enforcement endpoint. Recall record D-0330-2023. The FDA issues recall classifications as health-hazard assessments, not legal findings; for legal claims consult a licensed attorney.

Class II recall: Tacrolimus · FDA Drug Recalls